Preventing tomorrow's sudden cardiac death today. Part II: Translating sudden cardiac death risk assessment strategies into practice and policy

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 951-959

  Sanders, Gillian D ^a   Al Khatib, Sana M ^a   Berliner, Elise ^b   Bigger, J Thomas ^c   Buxton, Alfred E ^d   Califf, Robert M ^a   Carlson, Mark ^e   Curtis, Anne B ^f   Curtis, Jeptha P ^g   Domanski, Michael ^h   Fain, Eric ^e   Gersh, Bernard J ⁱ   Gold, Michael R ^j   Goldberger, Jeffrey ^k   Haghighi Mood, Ali ^l   Hammill, Stephen C ⁱ   Harder, Joel ^m   Healey, Jeffrey ⁿ   Hlatky, Mark A ^o   Hohnloser, Stefan H ^p   Lee, Kerry L ^a   Mark, Daniel B ^a   Mitchell, Brent ^q   Phurrough, Steve ^r   Prystowsky, Eric ^s   Smith, Joseph M ^t   Stockbridge, Norman ^u   Temple, Robert ^u   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e ST JUDE MEDICAL   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l Cambridge Heart Inc   (United States)

^m Heart Rhythm Society   (United States)

ⁿ MCMASTER UNIVERSITY   (Canada)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p GOETHE UNIVERSITY   (Germany)

^q LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^r Centers for Medicare   (United States)

^s ST VINCENT HOSPITAL   (United States)

^t Boston Scientific Corp   (United States)

^u CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BIOSTATISTICS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION MAKING; DEFIBRILLATOR; ECONOMICS; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEART DEATH; HIGH RISK POPULATION; HUMAN; MEDICAID; MEDICARE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; STRATIFICATION; SUDDEN DEATH;

AGE FACTORS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEART DISEASES; HUMANS; MALE; PATIENT SATISFACTION; POLICY MAKING; PRIMARY PREVENTION; RESEARCH; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 34249298301     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.002     Document Type: Article

References (32)

1. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
2. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
3. Buxton A.E. Sudden death after myocardial infarction-who needs prophylaxis and when?. N Engl J Med 352 (2005) 2638-2640
4. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
5. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
6. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
7. Mark D.B., Nelson C.L., Anstrom K.J., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114 (2006) 135-142
8. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
9. Zwanziger J., Hall W.J., Dick A.W., et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 2310-2318
10. Gould P.A., and Krahn A.D. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 295 (2006) 1907-1911
11. Reynolds M.R., Cohen D.J., Kugelmass A.D., et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 47 (2006) 2493-2947
12. Maisel W.H., Moynahan M., Zuckerman B.D., et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 295 (2006) 1901-1906
13. Hlatky M.A., and Mark D.B. The high cost of implantable defibrillators. Eur Heart J 28 (2007) 388-391
14. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
15. Al-Khatib SM, Sanders GD, Bigger JT, et al, for an expert panel participating in a Duke Center for the Prevention of Sudden Cardiac Death-sponsored conference. Preventing tomorrow's sudden cardiac death today. Part I: Current data on risk stratification for sudden cardiac death. Am Heart J [under review].
16. Bigger Jr. J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337 (1997) 1569-1575
17. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
18. Carlson M.D., Wilkoff B.L., Maisel W.H., et al. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE). Heart Rhythm 3 (2006) 1250-1273
19. Hauser R.G. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 45 (2005) 2022-2025
20. Bigger J.T., and Kleiger R.E. Individualizing decisions for patients with prophylactic implantable cardiac defibrillators subject to device advisories: a commentary. Am J Cardiol 98 (2006) 1291-1293
21. Anderson K.P. Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government. J Interv Card Electrophysiol 14 (2005) 71-78
22. Groeneveld P.W., Matta M.A., Suh J.J., et al. Costs and quality-of-life effects of implantable cardioverter-defibrillators. Am J Cardiol 98 (2006) 1409-1415
23. Zareba W., Moss A.J., Jackson Hall W., et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol 16 (2005) 1265-1270
24. Krahn A.D., Connolly S.J., Roberts R.S., et al. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 147 (2004) 837-840
25. Owens D.K., Sanders G.D., Heidenreich P.A., et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 144 (2002) 440-448
26. Klein R.C., Raitt M.H., Wilkoff B.L., et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 14 (2003) 940-948
27. Ellenbogen K.A., Levine J.H., Berger R.D., et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 113 (2006) 776-782
28. Al-Khatib S.M., Sanders G.D., Mark D.B., et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 149 (2005) 1020-1034
29. Owens D.K., Sanders G.D., Harris R.A., et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 126 (1997) 1-12
30. Sanders G.D., Hlatky M.A., Every N.R., et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 135 (2001) 870-883
31. Hlatky M.A., Sanders G.D., and Owens D.K. Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. Health Aff (Millwood) 24 (2005) 42-51
32. Neumann P.J., Rosen A.B., and Weinstein M.C. Medicare and cost-effectiveness analysis. N Engl J Med 353 (2005) 1516-1522